IL251562A0
(en )
2017-05-29
Method and compositions for targeting polyubiquitin
EP2010225A4
(en )
2010-04-21
Methods and compositions for targeting c-rel
EP1895838A4
(en )
2013-03-06
Compositions and methods
GB0522287D0
(en )
2005-12-07
Method and compositions
IL195619A0
(en )
2009-09-01
Compositions and methods for joininig non-conjoined iumens
IL185280A0
(en )
2008-02-09
Tetrahydroindolone and tetrahydroindazolone derivatives
IL191850A0
(en )
2008-12-29
Targeting vector-phospholipid conjugates
EP2043696A4
(en )
2012-01-04
Methods and compositions for targeting gc1qr/p32
GB0722090D0
(en )
2007-12-19
Amplifier
GB0601143D0
(en )
2006-03-01
Uses, methods and compositions
EP1949016A4
(en )
2010-09-08
Precision targeting
IL211089A0
(en )
2011-07-31
Compositions and methods for cell killing
EP2101731A4
(en )
2011-04-20
Endoxifen methods and compositions
EP1920064A4
(en )
2011-07-27
Compositions and methods for increasing amplification efficiency
IL195561A0
(en )
2011-08-01
Methods and compositions for targeting hepsin
EP2088865A4
(en )
2010-03-17
Guggulphospholipid methods and compositions
GB0617171D0
(en )
2006-10-11
Novel compositions and methods
GB0524927D0
(en )
2006-01-18
Compositions and method
IL227318A
(en )
2016-11-30
Compositions comprising an immune-stress-reducing enzyme
IL192957A0
(en )
2009-02-11
Methods and compositions for targeting relt
EP1976566A4
(en )
2010-10-20
Compositions and methods for altering rnai
GB0501348D0
(en )
2005-03-02
Compositions and methods
GB0511235D0
(en )
2005-07-06
Compositions and method
IL187587A0
(en )
2008-03-20
Methods and compositions for targeting ifnar2
EP1928507A4
(en )
2011-05-11
Targeted contrast agents and methods for targeting contrast agents